Dariush Hosseinzadeh

Dariush Hosseinzadeh

Auto-generated profile, based on publicly available information

Dariush Hosseinzadeh

Student of O. O. Bogomolets National Medical University, Kyiv, Ukraine

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2022 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
ZAZeinab Mohseni Afshar
Zeinab Mohseni Afshar
MBMohammad Barary
Mohammad Barary
RHRezvan Hosseinzadeh
Rezvan Hosseinzadeh
AAAmirmasoud Alijanpourotaghsara
Amirmasoud Alijanpourotaghsara
DHDariush Hosseinzadeh
Dariush Hosseinzadeh
ABArefeh Babazadeh
Arefeh Babazadeh
At the beginning of the current pandemic, it was believed that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection would induce lifelong immunity and that reinfections would be unlikely. However, after several cases of reinfection were documented in previously infected patients, this was understood to be a false assumption, and this waning humoral immunity has raised significant concerns. Accordingly, long-term and durable vaccine-induced antibody protection against infection have also become a challenge, as several breakthroughs of COVID-19 infection have been identified in individuals who were fully vaccinated. This review discusses the current evidence on breakthrough COVID-19 infections occurring after vaccination.

1 November 2023 in Infectious Disorders - Drug Targets
Verified
Journal Article
Closed access
PDF file
ZAZeinab Mohseni Afshar
Zeinab Mohseni Afshar
DHDariush Hosseinzadeh
Dariush Hosseinzadeh
RHRezvan Hosseinzadeh
Rezvan Hosseinzadeh
ABArefeh Babazadeh
Arefeh Babazadeh
AAAmirreza Allahgholipour
Amirreza Allahgholipour
Soheil EbrahimpourSoheil Ebrahimpour
Soheil Ebrahimpour
Remdesivir has appeared to be the most effective medication against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and is broadly administered to coronavirus disease 2019 (COVID-19) patients around the world. Remdesivir is an RNA polymerase inhibitor with a broad spectrum of antiviral activities against RNA viruses in in-vitro and in-vivo models of SARSCoV, the Middle East respiratory syndrome (MERS), and SARS-CoV-2. Remdesivir is the first Food and Drug Administration (FDA) approved anti-SARS-CoV-2 treatment for adult and pediatric patients and has been used for not hospitalized and have mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death. However, questions have been raised about the value of remdesivir in treating COVID-19, and governing bodies worldwide have been hesitant to approve this medication. Nevertheless, in the context of the public health emergency and the urgent need for effective treatments for patients with COVID-19, remdesivir has been approved by several authorities worldwide. Here, we discuss the characteristics and applications of remdesivir, and various challenging studies with different outcomes about its efficacy are also reviewed.